Loading
Adding mogamulizumab to intensive chemotherapy for newly diagnosed adult T-cell leukaemia raised the complete remission rate from 33 to 52 per cent, with more side effects.
A multicentre randomised phase 2 study (NCT01173887) of mLSG15, a dose-intensified chemotherapy, with or without mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma, assigned 1:1. The primary endpoint was the complete response rate; secondary endpoints included overall response and safety.
The randomised evidence for adding mogamulizumab to first-line chemotherapy in aggressive adult T-cell leukaemia/lymphoma: more complete remissions, more toxicity, and no survival comparison.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares mLSG15 with or without mogamulizumab, CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares JCOG9801, Adult T-cell leukaemia/lymphoma.
Shares mLSG15 with or without mogamulizumab, Adult T-cell leukaemia/lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/